Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Polek, T. C.
Right arrow Articles by Weigel, N. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Polek, T. C.
Right arrow Articles by Weigel, N. L.

Journal of Andrology, Vol 23, Issue 1 9-17, Copyright © 2002 by The American Society of Andrology

JOURNAL ARTICLE

Vitamin D and prostate cancer

T. C. Polek and N. L. Weigel
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA.

The original hypothesis of Schwartz and Hulka (1990) proposing that vitamin D deficiency may be a risk factor for prostate cancer has triggered many studies. Epidemiological studies have supported this hypothesis with findings that sunlight exposure is inversely proportional to prostate cancer mortality and that prostate cancer risk is greater in men with lower levels of vitamin D (Hanchette and Schwartz, 1992; Corder et al, 1993; Ahonen et al, 2000). Prostate cancer cells express receptors for 1,25(OH)2D3 and some cell lines are growth inhibited when treated with 1,25(OH)2D3 (reviewed in Blutt and Weigel, 1999). The mechanism of action of these growth inhibitory effects of 1,25(OH)2D3 in LNCaP cells involves G1 accumulation, induction of quiescence, and an increase in apoptosis of the cancer cells (Blutt et al, 1997, 2000a; Zhuang and Burnstein, 1998). In vivo, 1,25(OH)2D3 and its analogs slow tumor growth and hinder metastasis of prostate tumors in rodent models (Schwartz et al, 1995; Getzenberg et al, 1997; Lokeshwar et al, 1999; Blutt et al, 2000b), and 1,25(OH)2D3 may have clinically relevant effects (Gross et al, 1998). More work is required to elucidate the mechanism of 1,25(OH)2D3 action in prostate cancer cells and to identify optimal 1,25(OH)2D3 analogs in a search for compounds with a better separation of growth inhibitory effects from hypercalcemic effects.


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. N. Holick, J. L. Stanford, E. M. Kwon, E. A. Ostrander, S. Nejentsev, and U. Peters
Comprehensive Association Analysis of the Vitamin D Pathway Genes, VDR, CYP27B1, and CYP24A1, in Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1990 - 1999.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P. P Dwivedi, P. H Anderson, J. L Omdahl, H L. Grimes, H. A Morris, and B. K May
Identification of growth factor independent-1 (GFI1) as a repressor of 25-hydroxyvitamin D 1-alpha hydroxylase (CYP27B1) gene expression in human prostate cancer cells
Endocr. Relat. Cancer, June 1, 2005; 12(2): 351 - 365.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. G. Schwartz, D. Eads, A. Rao, S. D. Cramer, M. C. Willingham, T. C. Chen, D. P. Jamieson, L. Wang, K. L. Burnstein, M. F. Holick, et al.
Pancreatic cancer cells express 25-hydroxyvitamin D-1{alpha}-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3
Carcinogenesis, June 1, 2004; 25(6): 1015 - 1026.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
A. Rao, R. D. Woodruff, W. N. Wade, T. E. Kute, and S. D. Cramer
Genistein and Vitamin D Synergistically Inhibit Human Prostatic Epithelial Cell Growth
J. Nutr., October 1, 2002; 132(10): 3191 - 3194.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by The American Society of Andrology.